This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
Other namesEPI-002
Drug classNonsteroidal antiandrogen
CAS Number
PubChem CID
Chemical and physical data
Molar mass394.892 g/mol g·mol−1
3D model (JSmol)

Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]

See also


  1. ^ a b Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD (2013). "An androgen receptor N-terminal domain antagonist for treating prostate cancer". J. Clin. Invest. 123 (7): 2948–60. doi:10.1172/JCI66398. PMC 3696543. PMID 23722902.
  2. ^ McEwan, Iainj; Monaghan, Amye (2016). "A sting in the tail: The N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 18 (5): 687. doi:10.4103/1008-682X.181081. PMC 5000789. PMID 27212126.
  3. ^ Maughan BL, Antonarakis ES (2015). "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Curr Treat Options Oncol. 16 (12): 57. doi:10.1007/s11864-015-0375-z. PMID 26537882.